Ocugen (NASDAQ:OCGN) stock rose about 10% over the weekend. This comes after the company won U.S. Food and Drug Administration (FDA) clearance to advance its rare eye disease treatment to a Phase 3 trial. OCU400 is a gene therapy being developed for retinitis pigmentosa (RP). RP causes the retina at the back of the eye to break down over time, eventually resulting in blindness. Shares of OCGN are up more than 7% as of this writing, at around $1.90 per share and a market capitalization of roughly$485 millio ...